Highlights Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Market Closed - Deutsche Boerse AG Other stock markets 11:43:53 15/05/2024 am IST			5-day change	1st Jan Change
31.93 ^EUR	-2.24%		+1.92%	+30.91%

15/05	Merck to present new oncology data	CF
15/05	IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merck to present new oncology data	15/05	CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	15/05	MT
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	07/05	RE
Remsons, Daiichi Infotainments Form Joint Venture	30/04	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	29/04	MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	29/04	CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	29/04	AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	29/04	MT
Hipgnosis Songs Fund backs new Blackstone bid	29/04	AN
Scholz pledges further support for the pharmaceutical industry	25/04	DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	25/04	MT
AstraZeneca upbeat as cancer drugs underpin sales growth	25/04	AN
Daiichi Sankyo Company, Limited Announces Dividend for the Year Ended March 31, 2024, Payable on June 18, 2024 and Provides Dividend Guidance for Second Quarter of Fiscal Ending March 31, 2025	25/04	CI
Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025	25/04	CI
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	25/04	CI
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.	25/04	CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.	25/04	CI
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	10/04	MT
AstraZeneca hails neurological data for Ultomiris, Soliris	08/04	AN
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	06/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Highlights

Filters